Altair To Present at Upcoming Investor Conferences

TROY, Mich., June 01, 2022 (GLOBE NEWSWIRE) — Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence, today announced that James Scapa, chairman and chief executive officer, and Matt Brown, chief financial officer, will participate in the following investor conferences:

Event:   Nasdaq Investor Conference
When:   Tuesday, June 14, 2022
Time:   3:30 a.m. ET (8:30 a.m. BST)
Format:   Presentation
     
Event:   Berenberg Thematic Software Conference 2022
When:   Wednesday, June 15, 2022
Time:   8:00 a.m. ET (1:00 p.m. BST)
Format:   Fireside Chat

A live webcast, as well as a replay, of the presentations will be available on the company’s investor relations website at http://investor.altair.com.

About Altair

Altair is a global leader in computational science and artificial intelligence (AI) that provides software and cloud solutions in the areas of simulation, high-performance computing (HPC), data analytics, and AI. Altair enables organizations across all industries to compete more effectively and drive smarter decisions in an increasingly connected world – all while creating a greener, more sustainable future. To learn more, please visit www.altair.com.

Media Relations

Altair
Dave Simon
248-614-2400 ext. 332
[email protected]

Investor Relations

The Blueshirt Group
Monica Gould
212-871-3927
[email protected] 



Icosavax to Participate in the Jefferies Healthcare Conference

SEATTLE, June 01, 2022 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop combination vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Jefferies Healthcare Conference taking place from June 8-10, 2022.

Adam Simpson, Chief Executive Officer of Icosavax, is scheduled to present on Wednesday, June 8, at 11:30 a.m. Eastern Time.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.icosavax.com. The webcast replay will be available after the conclusion of the panel discussion for approximately 30 days.

About Icosavax

Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and an emerging program in influenza. Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.

For more information, visit www.icosavax.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectations and include, but are not limited to: the company’s expectation regarding the prophylactic and commercial potential of its vaccine product candidates and its platform technology. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the company’s business, including, without limitation: the early stage of the company’s development efforts; the company’s approach to the development of vaccine candidates, which is a novel and unproven approach; unexpected adverse side effects or inadequate immunogenicity or efficacy of the company’s vaccine candidates that may limit their development, regulatory approval, and/or commercialization; and other risks described in the company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s quarterly report on Form 10-Q for the quarter ended March 31, 2022 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Media Contact:

Jessica Yingling, Ph.D.
Little Dog Communications Inc.
[email protected]
858.344.8091

Investor Contact:

Laurence Watts
Gilmartin Group, LLC
[email protected]
619.916.7620



Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 4:00 p.m. E.T.

A live webcast of the Company presentation will be available through the investor relations section of the Company’s website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company’s website.

About Akero Therapeutics

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero’s lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2/F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Akero is headquartered in South San Francisco. Visit us at www.akerotx.com for more information.

Investor Contact:

Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]

Media Contact:

650.487.6488
[email protected]



Pool Corporation to Present at the Baird 2022 Global Consumer, Technology & Services Conference

COVINGTON, La., June 01, 2022 (GLOBE NEWSWIRE) — Pool Corporation (Nasdaq:POOL) announced today that Peter D. Arvan, President and Chief Executive Officer, Melanie M. Hart, Vice President and Chief Financial Officer, and Jeffrey M. Clay, President of Horizon Distributors, Inc., will be participating in the Baird 2022 Global Consumer, Technology & Services Conference at the InterContinental New York Barclay in New York, NY. The presentation will occur on Wednesday, June 8, 2022, at 10:15 AM Eastern Time. Informational materials used during the conference will be posted on POOLCORP’s website on the morning of the conference.

Pool Corporation is the world’s largest wholesale distributor of swimming pool and related backyard products. POOLCORP operates approximately 415 sales centers in North America, Europe and Australia through which it distributes more than 200,000 national brand and private label products to roughly 120,000 wholesale customers. For more information about POOLCORP, please visit www.poolcorp.com.

CONTACT:

Curtis J. Scheel
Director of Investor Relations
985.801.5341
[email protected]



Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences in June:

  • Jefferies Healthcare Conference: Fireside chat on Thursday, June 9, 2022 at 4:30 p.m. ET.

  • Goldman Sachs 43rd Annual Global Healthcare Conference: Fireside chat on Wednesday, June 15, 2022 at 9:20 a.m. PT.

The conference events will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. Replays of the webcasts will be available for 90 days following the event.

About Apellis 
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact:

Meredith Kaya
[email protected]
617.599.8178



Cytek Biosciences to Host Inaugural Analyst and Investor Day

FREMONT, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) announced today that it will host its inaugural Analyst and Investor Day on Wednesday June 22, with presentations beginning at 9:00 a.m. ET.

At this event, Cytek will highlight its portfolio of proprietary technology and related market opportunities, and host a series of presentations by various industry KOLs. Members of the leadership team will also participate in Q&A during the event.

A live webcast of the presentation will be available on Cytek’s investor relations website, https://investors.cytekbio.com/. A replay of the webcast will also be available following the presentation.

About Cytek Biosciences, Inc.

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems; its cell sorter, the Aurora CS; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Other than Cytek’s Northern Lights CLC system and certain reagents for use therewith, which are available for clinical use in countries where the regulatory approval has been obtained from the local regulatory authorities, including China and the European Union, Cytek’s products are for research use only and not for use in diagnostic procedures. Please contact your local sales representatives for the status of local regulatory approval.

Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and corporate Twitter account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and Twitter account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Media Contact:

Stephanie Olsen
Lages & Associates
(949) 453-8080
[email protected]

Investor Relations Contact:

Paul D. Goodson
Head of Investor Relations
[email protected]



BlackLine Announces Participation in Upcoming Investor Conferences

LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) — BlackLine, Inc. (Nasdaq: BL) today announced that BlackLine’s management team will participate in the following investor conferences:

Baird Global Consumer Tech & Services Conference

Monday, June 6th, 2022
Presentation Time: 11:35am PT
Location: New York, NY

William Blair & Company 42nd Annual Growth Stock Conference

Tuesday, June 7th, 2022
Presentation Time: 10:00am PT
Location: Chicago, IL

The presentations will be webcast live and replays will be available on BlackLine’s investor relations website at https://investors.blackline.com.

About BlackLine

Companies come to BlackLine (Nasdaq: BL) because their traditional manual accounting processes are not sustainable. BlackLine’s cloud-based financial operations management platform and market-leading customer service help companies move to modern accounting by unifying their data and processes, automating repetitive work, and driving accountability through visibility. BlackLine provides solutions to manage and automate financial close, accounts receivable and intercompany accounting processes, helping large enterprises and midsize companies across all industries do accounting work better, faster and with more control.

More than 3,800 customers trust BlackLine to help them close faster with complete and accurate results. The company is the pioneer of the cloud financial close market and recognized as the leader by customers at leading end-user review sites including Gartner Peer Insights, G2 and TrustRadius. BlackLine is a global company with operations in major business centers around the world including Los Angeles, New York, the San Francisco Bay area, London, Paris, Frankfurt, Tokyo, Singapore and Sydney. For more information, please visit blackline.com.

Investor Relations Contact:

BlackLine IR
[email protected]



Health Catalyst to Participate in Upcoming Investor Conferences

SALT LAKE CITY, June 01, 2022 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Bryan Hunt, Chief Financial Officer, and Adam Brown, Senior Vice President of Investor Relations and FP&A, will participate in the following upcoming investor conferences:

  • William Blair’s 42nd Annual Growth Stock Conference, being held in Chicago on Tuesday, June 7, 2022, including a presentation at 12:40 pm CT. The replay of the presentation will be available online at https://ir.healthcatalyst.com.
  • Stifel Cross-Sector Insight Conference, being held in Boston on Wednesday, June 8, 2022, including a presentation at 3:35 pm ET.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Health Catalyst Investor Relations Contact:

Adam Brown
Senior Vice President, Investor Relations and FP&A
+1 (855)-309-6800
[email protected]

Health Catalyst Media Contact:

Amanda Hundt
+1 (575)-491-0974
[email protected]



AMSC Reports Fourth Quarter and Full Fiscal Year 2021 Financial Results and Provides Business Outlook

Company to host conference call tomorrow, June 2 at 10:00 am ET

AYER, Mass., June 01, 2022 (GLOBE NEWSWIRE) — AMSC (Nasdaq: AMSC), a leading system provider of megawatt-scale power resiliency solutions that orchestrate the rhythm and harmony of power on the grid™, and that protect and expand the capability and resiliency of our Navy’s fleet, today reported financial results for its fourth quarter and fiscal year ended March 31, 2022 (“fiscal 2021”).

Revenues for the fourth quarter of fiscal 2021 were $28.3 million compared with $21.2 million for the same period of fiscal 2020. The year-over-year increase was a result of higher Grid segment revenues, primarily driven by strong new energy power system sales.

AMSC’s net loss for the fourth quarter of fiscal 2021 was $5.0 million, or $0.18 per share, compared to net loss of $7.6 million, or $0.29 per share, for the same period of fiscal 2020. The Company’s non-GAAP net loss for the fourth quarter of fiscal 2021 was $4.7 million, or $0.17 per share, compared with a non-GAAP net loss of $5.6 million, or $0.21 per share, in the same period of fiscal 2020. Please refer to the financial table below for a reconciliation of GAAP to non-GAAP results.

Revenues for fiscal year 2021 were $108.4 million as compared to $87.1 million in fiscal year 2020. The increase in revenues was driven by higher new energy power system sales, as well as higher ship protection system (SPS) revenue. AMSC reported a net loss for the fiscal year 2021 of $19.2 million, or $0.71 per diluted share, compared to net loss of $22.7 million, or $0.95 per diluted share in fiscal year 2020. The Company’s non-GAAP net loss for fiscal 2021 was $17.1 million, or $0.63 per share, compared with a non-GAAP net loss of $14.1 million, or $0.59 per share, for fiscal 2020.  Please refer to the financial table below for a reconciliation of GAAP to non-GAAP results.

Cash, cash equivalents, marketable securities and restricted cash on March 31, 2022 totaled $49.5 million.  

“Fiscal 2021 was another year of significant grid growth and grid diversification for AMSC,” said Daniel P. McGahn, Chairman, President and CEO, AMSC. “We accomplished these important goals despite the global pandemic that disrupted business supply chains and impacted prices of raw materials for virtually all businesses. Our team here at AMSC responded to the challenge and successfully positioned the Company for a potential rebound in wind and improved margins for fiscal 2022.” 

Business Outlook

For the first quarter ending June 30, 2022, AMSC expects that its revenues will be in the range of $23 million to $26 million. The Company’s net loss for the first quarter of fiscal 2022 is expected not to exceed $8.9 million, or $0.32 per share.  The Company’s net loss guidance assumes no changes in contingent consideration. The Company’s non-GAAP net loss (as defined below) is expected not to exceed $6.9 million, or $0.25 per share.  The Company expects operating cash flow to be a burn of $4 million to $6 million in the first quarter of fiscal 2022.  The Company expects cash, cash equivalents, marketable securities and restricted cash on June 30, 2022, to be no less than $43 million.

Conference Call Reminder

In conjunction with this announcement, AMSC management will participate in a conference call with investors beginning at 10:00 a.m. Eastern Time on Thursday, June 2, 2022, to discuss the Company’s financial results and business outlook. Those who wish to listen to the live or archived conference call webcast should visit the “Investors” section of the Company’s website at http://www.amsc.com/investors. To preregister for the call, go to ClickToJoinLink. Callers who click the link will be able to enter their information to gain immediate access to the call and bypass the live operator. Participants may preregister 15 minutes prior to the scheduled start time.  The live call can also be accessed by dialing 888-394-8218 or 323-794-2588 and using conference ID 4095203. A replay of the call may be accessed 2 hours following the call by dialing 888-203-1112 or 719-457-0820 and using conference passcode 4095203.

About AMSC (Nasdaq: AMSC)

AMSC generates the ideas, technologies and solutions that meet the world’s demand for smarter, cleaner … better energy™. Through its Gridtec™ Solutions, AMSC provides the engineering planning services and advanced grid systems that optimize network reliability, efficiency and performance. Through its Marinetec™ Solutions, AMSC provides ship protection and is developing propulsion and power management solutions designed to help fleets increase system efficiencies, enhance power quality and boost operational safety. Through its Windtec™ Solutions, AMSC provides wind turbine electronic controls and systems, designs and engineering services that reduce the cost of wind energy. The Company’s solutions are enhancing the performance and reliability of power networks, increasing the operational safety of navy fleets, and powering gigawatts of renewable energy globally. Founded in 1987, AMSC is headquartered near Boston, Massachusetts with operations in Asia, Australia, Europe and North America. For more information, please visit www.amsc.com.

AMSC, American Superconductor, D-VAR, D-VAR VVO, Gridtec, Marintec, Windtec, Neeltran, NEPSI, Smarter, Cleaner … Better Energy and Orchestrate the Rhythm and Harmony of Power on the Grid are trademarks or registered trademarks of American Superconductor Corporation. All other brand names, product names, trademarks or service marks belong to their respective holders.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this release regarding our goals and strategies; growth of our business, including our Grid business; our expected GAAP and non-GAAP financial results for the quarter ending June 30, 2022, our expected cash, cash equivalents, marketable securities, and restricted cash balance on June 30, 2022; a potential rebound in wind and improved margins for fiscal 2022; and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements represent management’s current expectations and are inherently uncertain. There are a number of important factors that could materially impact the value of our common stock or cause actual results to differ materially from those indicated by such forward-looking statements. These important factors include, but are not limited to: We have a history of operating losses, which may continue in the future. Our operating results may fluctuate significantly from quarter to quarter and may fall below expectations in any particular fiscal quarter; We have a history of negative operating cash flows, and we may require additional financing in the future, which may not be available to us; We may be required to issue performance bonds or provide letters of credit, which restricts our ability to access any cash used as collateral for the bonds or letters of credit; Changes in exchange rates could adversely affect our results of operations; If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired and may lead investors and other users to lose confidence in our financial data; We may not realize all of the sales expected from our backlog of orders and contracts; Our contracts with the U.S. government are subject to audit, modification or termination by the U.S. government and include certain other provisions in favor of the government. The continued funding of such contracts remains subject to annual congressional appropriation, which, if not approved, could reduce our revenue and lower or eliminate our profit; The COVID-19 pandemic could adversely impact our business, financial condition and results of operations;
Changes in U.S. government defense spending could negatively impact our financial position, results of operations, liquidity and overall business; We rely upon third-party suppliers for the components and subassemblies of many of our Grid and Wind products, making us vulnerable to supply shortages and price fluctuations, which could harm our business; Uncertainty surrounding our prospects and financial condition may have an adverse effect on our customer and supplier relationships; We have not manufactured our Amperium wire in commercial quantities, and a failure to manufacture our Amperium wire in commercial quantities at acceptable cost and quality levels would substantially limit our future revenue and profit potential; Our success is dependent upon attracting and retaining qualified personnel and our inability to do so could significantly damage our business and prospects; A significant portion of our Wind segment revenues are derived from a single customer. If this customer’s business is negatively affected, it could adversely impact our business; Our success in addressing the wind energy market is dependent on the manufacturers that license our designs;
Our business and operations would be adversely impacted in the event of a failure or security breach of our or any critical third parties information technology infrastructure and networks; Failure to comply with evolving data privacy and data protection laws and regulations or to otherwise protect personal data, may adversely impact our business and financial results; Many of our revenue opportunities are dependent upon subcontractors and other business collaborators; If we fail to implement our business strategy successfully, our financial performance could be harmed; Problems with product quality or product performance may cause us to incur warranty expenses and may damage our market reputation and prevent us from achieving increased sales and market share; Many of our customers outside of the United States may be either directly or indirectly related to governmental entities, and we could be adversely affected by violations of the United States Foreign Corrupt Practices Act and similar worldwide anti-bribery laws outside the United States; We have had limited success marketing and selling our superconductor products and system-level solutions, and our failure to more broadly market and sell our products and solutions could lower our revenue and cash flow;
We may acquire additional complementary businesses or technologies, which may require us to incur substantial costs for which we may never realize the anticipated benefits; Our success depends upon the commercial adoption of the REG system, which is currently limited, and a widespread commercial market for our products may not develop; Adverse changes in domestic and global economic conditions could adversely affect our operating results; We have operations in, and depend on sales in, emerging markets, including India, and global conditions could negatively affect our operating results or limit our ability to expand our operations outside of these markets. Changes in Indias political, social, regulatory and economic environment may affect our financial performance; Our products face competition, which could limit our ability to acquire or retain customers; Our international operations are subject to risks that we do not face in the United States, which could have an adverse effect on our operating results; Growth of the wind energy market depends largely on the availability and size of government subsidies, economic incentives and legislative programs designed to support the growth of wind energy; Lower prices for other fuel sources may reduce the demand for wind energy development, which could have a material adverse effect on our ability to grow our Wind business; The increasing focus on environmental sustainability and social initiatives could increase our costs, and inaction could harm our reputation and adversely impact our financial results; We may be unable to adequately prevent disclosure of trade secrets and other proprietary information;Our patents may not provide meaningful protection for our technology, which could result in us losing some or all of our market position; There are a number of technological challenges that must be successfully addressed before our superconductor products can gain widespread commercial acceptance, and our inability to address such technological challenges could adversely affect our ability to acquire customers for our products; Third parties have or may acquire patents that cover the materials, processes and technologies we use or may use in the future to manufacture our Amperium products, and our success depends on our ability to license such patents or other proprietary rights; Our technology and products could infringe intellectual property rights of others, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and disrupt our business; We face risks related to our legal proceedings; We face risks related to our common stock; and the other important factors discussed under the caption “Risk Factors” in Part 1. Item 1A of our Form 10-K for the fiscal year ended March 31, 2022, and our other reports filed with the SEC. These important factors, among others, could cause actual results to differ materially from those indicated by forward-looking statements made herein and presented elsewhere by management from time to time. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

 
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)
             
    Three Months Ended     Twelve Months Ended  
    March 31,     March 31,  
    2022     2021     2022     2021  
Revenues                                
Grid   $ 25,706     $ 19,380     $ 98,876     $ 70,528  
Wind     2,602       1,784       9,559       16,597  
Total revenues     28,308       21,164       108,435       87,125  
                                 
Cost of revenues     25,018       18,226       94,943       69,671  
                                 
Gross margin     3,290       2,938       13,492       17,454  
                                 
Operating expenses:                                
Research and development     2,102       2,768       10,470       11,015  
Selling, general and administrative     6,880       6,713       27,494       25,322  
Amortization of acquisition related intangibles     627       621       2,467       1,222  
(Gain) loss on contingent consideration     (1,410 )     320       (5,850 )     3,060  
Total operating expenses     8,199       10,422       34,581       40,619  
                                 
Operating loss     (4,909 )     (7,484 )     (21,089 )     (23,165 )
                                 
Interest income, net     7       53       75       426  
Other income (expense), net     (33 )     149       (28 )     (771 )
Loss before income tax expense     (4,935 )     (7,281 )     (21,042 )     (23,510 )
                                 
Income tax expense (benefit)     97       335       (1,849 )     (832 )
                                 
Net loss   $ (5,032 )   $ (7,616 )   $ (19,193 )   $ (22,678 )
                                 
Net loss per common share                                
Basic   $ (0.18 )   $ (0.29 )   $ (0.71 )   $ (0.95 )
Diluted   $ (0.18 )   $ (0.29 )   $ (0.71 )   $ (0.95 )
                                 
Weighted average number of common shares outstanding                                
Basic     27,383       26,533       27,203       23,879  
Diluted     27,383       26,533       27,203       23,879  
                                 

CONSOLIDATED BALANCE SHEET

(In thousands, except per share data)
 
             
    March 31,     March 31,  
    2022     2021  
ASSETS                
Current assets:                
Cash and cash equivalents   $ 40,584     $ 67,814  
Marketable securities           5,140  
Accounts receivable     20,280       13,267  
Inventory     23,666       13,306  
Prepaid expenses and other current assets     7,052       3,546  
Restricted cash     2,754       2,157  
          Total current assets     94,336       105,230  
                 
Property, plant and equipment, net     13,656       8,997  
Intangibles, net     11,311       9,153  
Right-of-use asset     3,502       3,747  
Goodwill     43,471       34,634  
Restricted cash     6,148       5,568  
Deferred tax assets     1,224       1,223  
Other assets     239       314  
          Total assets   $ 173,887     $ 168,866  
                 
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                 
Current liabilities:                
Accounts payable and accrued expenses   $ 29,140     $ 19,810  
Lease liability, current portion     740       612  
Debt, current portion     72        
Contingent consideration     1,200       7,050  
Deferred revenue, current portion     22,812       13,266  
          Total current liabilities     53,964       40,738  
                 
Deferred revenue, long term portion     7,222       7,991  
Lease liability, long term portion     2,900       3,246  
Deferred tax liabilities     297       274  
Debt, long-term portion     90        
Other liabilities     25       25  
          Total liabilities     64,498       52,274  
                 
Stockholders’ equity:                
Common stock, $0.01 par value, 75,000,000 shares authorized; 28,919,990 and 27,988,536
shares issued and 28,522,359 and 27,593,400 shares outstanding at March 31, 2022 and 2021,
respectively
    289       280  
Additional paid-in capital     1,133,536       1,121,495  
Treasury stock, at cost, 397,631 and 395,136 shares at March 31, 2022 and 2021, respectively     (3,639 )     (3,593 )
Accumulated other comprehensive loss     (291 )     (277 )
Accumulated deficit     (1,020,506 )     (1,001,313 )
          Total stockholders’ equity     109,389       116,592  
          Total liabilities and stockholders’ equity   $ 173,887     $ 168,866  
                 

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)
       
    Year Ended March 31,  
    2022     2021  
Cash flows from operating activities:                
Net loss   $ (19,193 )   $ (22,678 )
Adjustments to reconcile net loss to net cash used in operations:                
Depreciation and amortization     5,341       5,352  
Stock-based compensation expense     4,661       3,485  
Provision for excess and obsolete inventory     1,902       1,762  
Deferred income taxes     (2,403 )     (1,221 )
Change in fair value of contingent consideration     (5,850 )     3,060  
Non-cash interest income     (49 )     (94 )
Other non-cash items     525       272  
Unrealized foreign exchange loss/(gain) on cash and cash equivalents     (186 )     363  
Changes in operating asset and liability accounts:                
Accounts receivable     (3,760 )     5,193  
Inventory     (3,307 )     8,106  
Prepaid expenses and other current assets     (420 )     823  
Accounts payable and accrued expenses     4,695       (5,047 )
Deferred revenue     (933 )     (8,057 )
Net cash used in operating activities     (18,977 )     (8,681 )
                 
Cash flows from investing activities:                
Purchase of property, plant and equipment     (938 )     (1,764 )
Sale of marketable securities           30,152  
Cash paid for acquisition, net of cash received     (11,479 )     (26,000 )
Proceeds from the maturity of marketable securities     5,189        
Change in other assets     65       81  
Net cash provided by (used in) investing activities     (7,163 )     2,469  
                 
Cash flows from financing activities:                
Repurchase of treasury stock     (46 )     (927 )
Repayment of debt     (53 )      
Proceeds from public equity offering, net           51,477  
Proceeds from exercise of employee stock options and ESPP     241       278  
Net cash provided by financing activities     142       50,828  
                 
Effect of exchange rate changes on cash, cash equivalents and restricted cash     (55 )     59  
                 
Net increase (decrease) in cash, cash equivalents and restricted cash     (26,053 )     44,675  
Cash, cash equivalents and restricted cash at beginning of year     75,539       30,864  
Cash, cash equivalents and restricted cash at end of year   $ 49,486     $ 75,539  
                 

RECONCILIATION OF GAAP NET LOSS TO NON-GAAP NET LOSS

(In thousands, except per share data)
             
    Three Months Ended
March 31,
    Year Ended March 31,  
    2022     2021     2022     2021  
Net loss   $ (5,032 )   $ (7,616 )   $ (19,193 )   $ (22,678 )
Stock-based compensation     1,147       888       4,661       3,485  
Amortization of acquisition-related intangibles     644       811       2,623       1697  
Change in fair value of contingent consideration     (1,410 )     320       (5,850 )     3,060  
Acquisition costs                 681       313  
Non-GAAP net loss     (4,650 )     (5,597 )     (17,078 )     (14,123 )
                                 
Non-GAAP net loss per share   $ (0.17 )   $ (0.21 )   $ (0.63 )   $ (0.59 )
Weighted average shares outstanding – basic and diluted     27,383       26,533       27,203       23,879  
                                 

Reconciliation of Forecast GAAP Net Loss to Non-GAAP Net Loss

(In millions, except per share data)
       
    Three months
ending
 
    June 30, 2022  
Net loss   $ (8.9 )
Stock-based compensation     1.3  
Amortization of acquisition-related intangibles     0.7  
Non-GAAP net loss   $ (6.9 )
Non-GAAP net loss per share   $ (0.25 )
Shares outstanding     27.6  
         

Note: Non-GAAP net loss is defined by the Company as net income (loss) before; stock-based compensation; amortization of acquisition-related intangibles; acquisition costs; changes in fair value of contingent consideration; other non-cash or unusual charges, and the tax effect of adjustments calculated at the relevant rate for our non-GAAP metric. The Company believes non-GAAP net loss assists management and investors in comparing the Company’s performance across reporting periods on a consistent basis by excluding these non-cash, non-recurring or other charges that it does not believe are indicative of its core operating performance. Actual GAAP and non-GAAP net loss for the fiscal quarter ending June 30, 2022, including the above adjustments, may differ materially from those forecasted in the table above, including as a result of change in the fair value of contingent consideration.

Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP measures included in this release, however, should be considered in addition to, and not as a substitute for or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of GAAP to non-GAAP net loss is set forth in the table above.

AMSC Contacts

Investor Relations Contact:

LHA Investor Relations
Carolyn Cappaccio
(212) 838-3777
[email protected] 

Public Relations Contact:

RooneyPartners LLC
Joe Luongo
914-906-5903
[email protected] 

AMSC Communications Manager:

Nicol Golez
Phone: 978-399-8344
Email: [email protected] 



Credo Technology Group Holding Ltd Reports Fourth Quarter and Fiscal Year 2022 Financial Results

SAN JOSE, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Credo Technology Group Holding Ltd (NASDAQ: CRDO), an innovator in providing secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase throughout the data infrastructure market, today reported financial results for the fourth quarter and full fiscal year, ended April 30, 2022.

Q4 Financial Highlights

  • Revenue of $37.5 million, grew by 90.0% year on year
  • GAAP gross margin of 63.3% and non-GAAP gross margin of 63.7%
  • GAAP operating expenses of $30.1 million and non-GAAP operating expenses of $21.6 million
  • GAAP net loss of $5.4 million and non-GAAP net income of $2.8 million
  • GAAP net loss per share of $0.04 and non-GAAP diluted net income per share of $0.02
  • During the quarter, Credo sold an additional three million ordinary shares in connection with its initial public offering and received net proceeds of $28.1 million after deducting underwriting discount and commission
  • Ending Cash Balance of $259.3 million

Management Commentary

Bill Brennan, Credo’s President and Chief Executive Officer, stated, “Fiscal 2022 was a year of tremendous achievement for Credo. Our highlights included completing our initial public offering in January 2022 and achieving record revenue of $106.5 million, up more than 80% from prior year. We also delivered record results in the most recent quarter, despite the complexities we faced. During our fiscal fourth quarter, we recorded revenue of $37.5 million, a 90.0% increase year over year. We had growth in every of part of our business in fiscal 2022, and we expect the same in fiscal 2023.”

First Quarter of Fiscal 2023 Financial Outlook

  • Revenue is expected to be between $43.5 million to $47.5 million, up 324% year over year at the midpoint
  • GAAP gross margin is expected to be between 58.5%-60.5% and non-GAAP gross margin is expected to be between 59.0%-61.0%
  • GAAP operating expenses are expected to be between $27.5 million to $29.5 million and non-GAAP operating expenses are expected to be between $21.5 million to $23.5 million

Conference Call

Credo will conduct a conference call on Wednesday, June 1, 2022, at 2:00 p.m. Pacific Time to discuss its financial results for the fiscal fourth quarter and fiscal year ended April 30, 2022. Interested parties may join the conference call beginning at 2:00 p.m. Pacific Time on Wednesday, June 1, 2022 via telephone by dialing 1-855-553-1968 in the U.S., or for international callers, by dialing 1-409-981-0977 and entering conference ID 4861225. A telephone replay will be available until June 8, 2022, by dialing 1-855-859-2056 in the U.S., or for international callers, 1-404-537-3406 with conference ID 4861225. A live webcast of the conference call will be available on Credo’s Investor Relations website at http://investors.credosemi.com/. A replay of the webcast will be available via the web at http://investors.credosemi.com/

Discussion of Non-GAAP Financial Measures

This press release contains references to non-GAAP financial measures of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net income (loss) and non-GAAP diluted net income (loss) per share. Reconciliation of these non-GAAP measures to its comparable GAAP measure is included below. This non-GAAP information should not be construed as an alternative to the reported results determined in accordance with GAAP. It is provided solely to assist in an investor’s understanding of these items on the comparability of the Company’s operations.

Non-GAAP financial measures exclude the effect of share-based compensation expenses, warrant contra revenue, asset impairment charges (if applicable), and the related tax effect adjustment to the provision for income taxes.

Credo uses a full-year non-GAAP tax rate to compute the non-GAAP tax provision. This full-year non-GAAP tax rate is based on Credo’s annual GAAP income, adjusted to exclude non-GAAP items, as well as the effects of significant non-recurring and period specific tax items which vary in size and frequency. Credo’s non-GAAP tax rate is determined on an annual basis and may be adjusted during the year to take into account events that may materially affect the non-GAAP tax rate such as tax law changes, significant changes in Credo’s geographic mix of revenue and expenses, or changes to Credo’s corporate structure.

GAAP diluted net income (loss) per share is calculated using basic weighted average shares outstanding when there is a GAAP net loss, and calculated using diluted weighted average shares outstanding when there is a GAAP net income. Non-GAAP diluted net income per share is calculated using diluted weighted average shares outstanding.

Credo believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to Credo’s financial condition and results of operations. While Credo uses non-GAAP financial measures as a tool to enhance its understanding of certain aspects of its financial performance, Credo does not consider these measures to be a substitute for, or superior to, financial measures calculated in accordance with GAAP. Consistent with this approach, Credo believes that disclosing non-GAAP financial measures to the readers of its financial statements provides such readers with useful supplemental data that, while not a substitute for GAAP financial measures, allows for greater transparency in the review of its financial and operational performance.

Externally, management believes that investors may find Credo’s non-GAAP financial measures useful in their assessment of Credo’s operating performance and the valuation of Credo. Internally, Credo’s non-GAAP financial measures are used in the following areas:

  • Management’s evaluation of Credo’s operating performance;
  • Management’s establishment of internal operating budgets; and
  • Management’s performance comparisons with internal forecasts and targeted business models

Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of Credo’s business as determined in accordance with GAAP. As a result, you should not consider these measures in isolation or as a substitute for analysis of Credo’s results as reported under GAAP. The exclusion of the above items from our GAAP financial metrics does not necessarily mean that these costs are unusual or infrequent.

Forward-Looking Statements under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the federal securities laws that involve risks and uncertainties. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to any statements regarding: launches of new or expansion of existing products or services, technology developments and innovation; our plans, strategies or objectives with respect to future operations; future financial results; expectations regarding the markets and industries in which Credo conducts business; and assumptions underlying any of the foregoing. Words such as “anticipates,” “expects,” “intends,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “can,” “may,” “will,” “would,” “outlook,” “forecast,” “targets” and similar expressions identify such forward-looking statements. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties. Readers are encouraged to review risk factors and all other disclosures appearing in the Company’s Prospectus as filed with the Securities and Exchange Commission (SEC) on January 26, 2022, as well as Credo’s other filings with the SEC, for further information on risks and uncertainties that could affect Credo’s business, financial condition and results of operation. Copies of these filings are available from the SEC, the Company’s website or the Company’s investor relations department. Forward-looking statements speak only as of the date they are made. Credo assumes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date herein.

About Credo

Our mission is to deliver high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. Credo is an innovator in providing secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. Our innovations ease system bandwidth bottlenecks while simultaneously improving on power, security and reliability. Our connectivity solutions are optimized for optical and electrical Ethernet applications, including the emerging 100G (or Gigabits per second), 200G, 400G and 800G port markets. Our products are based on our proprietary Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies. Our product families include integrated circuits (ICs), Active Electrical Cables (AECs) and SerDes Chiplets. Our intellectual property (IP) solutions consist primarily of SerDes IP licensing.

Investor Relations Contact:

Dan O’Neil
[email protected]

Credo Technology Group Holding Ltd

Condensed Consolidated Statements of Operations (Unaudited)

(In thousands, except per share amounts)

  Three Months Ended   Year Ended
  April 30,
2022
  January
31, 2022
  April 30,
2021
  April 30,
2022
  April 30,
2021
Revenue:                  
Product sales $ 25,298     $ 22,706     $ 8,747     $ 73,721     $ 27,477  
Product engineering services   1,113       3,954       4,230       7,741       9,579  
IP license   11,115       5,022       5,722       23,309       17,273  
IP license engineering services         118       1,051       1,706       4,368  
Total revenue   37,526       31,800       19,750       106,477       58,697  
Cost of revenue:                  
Cost of product sales revenue   13,646       12,230       5,135       40,082       16,071  
Cost of product engineering services revenue   111       410       874       1,918       3,168  
Cost of IP license engineering services revenue         48       377       462       1,180  
Total cost of revenue   13,757       12,688       6,386       42,462       20,419  
Gross profit   23,769       19,112       13,364       64,015       38,278  
Operating expenses:                  
Research and development   15,461       10,995       8,209       47,949       34,845  
Selling, general and administrative   11,507       8,568       7,065       34,900       28,667  
Impairment charges   3,134                   3,134        
Total operating expenses   30,102       19,563       15,274       85,983       63,512  
Operating loss   (6,333 )     (451 )     (1,910 )     (21,968 )     (25,234 )
Other income (expense), net   (175 )     (80 )     (22 )     (245 )     (62 )
Loss before income taxes   (6,508 )     (531 )     (1,932 )     (22,213 )     (25,296 )
Provision (benefit) for income taxes   (1,153 )     (387 )     1,154       (37 )     2,215  
Net loss $ (5,355 )   $ (144 )   $ (3,086 )   $ (22,176 )   $ (27,511 )
                   
Net loss per share:                  
Basic and diluted $ (0.04 )   $     $ (0.05 )   $ (0.25 )   $ (0.40 )
Weighted-average shares used in computing net loss per share:                  
Basic and diluted   144,501       73,815       67,719       88,398       69,099  
                                       



Credo Technology Group Holding Ltd


Condensed Consolidated Balance Sheets (Unaudited)

(In thousands)

    April 30, 2022   April 30, 2021
Assets
Current Assets:        
Cash and cash equivalents   $ 259,322     $ 103,757  
Accounts receivable     29,524       13,645  
Inventories     27,337       7,104  
Contract assets     10,071       4,562  
Prepaid expenses and other current assets     5,923       8,731  
Total current assets     332,177       137,799  
Property and equipment, net     21,844       14,231  
Right of use assets     16,954        
Other non-current assets     4,714       3,460  
Total assets   $ 375,689     $ 155,490  
Liabilities, Convertible Preferred Shares and Shareholders’ Equity (Deficit)
Current Liabilities:        
Accounts payable   $ 8,487     $ 3,590  
Accrued compensation and benefits     4,713       1,549  
Accrued expenses and other current liabilities     12,063       3,277  
Deferred revenue     1,234       4,116  
Total current liabilities     26,497       12,532  
Non-current operating lease liabilities     14,809        
Other non-current liabilities     220       424  
Total liabilities     41,526       12,956  
Convertible preferred shares           197,965  
Shareholders’ equity (deficit):        
Ordinary shares     7       3  
Additional paid in capital     424,562       12,592  
Accumulated other comprehensive income     23       227  
Accumulated deficit     (90,429 )     (68,253 )
Total shareholders’ equity (deficit)     334,163       (55,431 )
Total liabilities, convertible preferred shares and shareholders’ equity (deficit)   $ 375,689     $ 155,490  
                 



Credo Technology Group Holding Ltd


Reconciliations from GAAP to Non-GAAP (Unaudited)

(In thousands, except percentages and per share amounts)

  Three Months Ended   Year Ended
  April 30,
2022
  January
31, 2022
  April 30,
2021
  April 30,
2022
  April 30,
2021
GAAP gross profit $ 23,769     $ 19,112     $ 13,364     $ 64,015     $ 38,278  
Reconciling items:                  
Warrant contra revenue   233       407             640        
Share-based compensation   40       46       46       220       183  
Total reconciling items:   273       453       46       860       183  
Non-GAAP gross profit $ 24,042     $ 19,565     $ 13,410     $ 64,875     $ 38,461  
                   
GAAP gross margin   63.3 %     60.1 %     67.7 %     60.1 %     65.2 %
Non-GAAP gross margin   63.7 %     60.7 %     67.9 %     60.6 %     65.5 %
                   
                   
Total GAAP operating expenses $ 30,102     $ 19,563     $ 15,274     $ 85,983     $ 63,512  
Reconciling item:                  
Share-based compensation   (5,328 )     (1,392 )     (872 )     (8,968 )     (13,723 )
Impairment charges   (3,134 )                 (3,134 )      
Total reconciling items:   (8,462 )     (1,392 )     (872 )     (12,102 )     (13,723 )
Total Non-GAAP operating expenses $ 21,640     $ 18,171     $ 14,402     $ 73,881     $ 49,789  
                   
                   
GAAP net loss $ (5,355 )   $ (144 )   $ (3,086 )   $ (22,176 )   $ (27,511 )
Reconciling items:                  
Warrant contra revenue   233       407             640        
Share-based compensation   5,368       1,438       918       9,188       13,906  
Impairment charges   3,134                   3,134        
Pre-tax total reconciling items   8,735       1,845       918       12,962       13,906  
Other income tax effects and adjustments   (611 )     700       (121 )     (1,049 )     (300 )
Non-GAAP net income/(loss) $ 2,769     $ 2,401     $ (2,289 )   $ (10,263 )   $ (13,905 )
                   
                   
GAAP weighted average shares – basic   144,501       73,815       67,719       88,398       69,099  
GAAP weighted average shares – diluted   144,501       73,815       67,719       88,398       69,099  
Non-GAAP adjustment   13,732       10,373                    
Non-GAAP weighted average shares – diluted   158,233       84,187       67,719       88,398       69,099  
                   
GAAP diluted net loss per share $ (0.04 )   $     $ (0.05 )   $ (0.25 )   $ (0.40 )
Non-GAAP diluted net income/(loss) per share $ 0.02     $ 0.03     $ (0.03 )   $ (0.12 )   $ (0.20 )
                                       



Credo Technology Group Holding Ltd


Reconciliation of GAAP Forward-Looking Estimates to Non-GAAP Forward-Looking Estimates

(In millions, except percentages)

    Three Months Ended July 30, 2022
    Low   High
         
GAAP gross margin     58.5 %     60.5 %
Reconciling items:        
Warrant contra revenue     0.4 %     0.4 %
Share-based compensation     0.1 %     0.1 %
Total reconciling items:     0.5 %     0.5 %
Non-GAAP gross margin     59.0 %     61.0 %
         
         
Total GAAP operating expenses   $ 27.5     $ 29.5  
Reconciling item:        
Share-based compensation     6.0       6.0  
Total reconciling items:     6.0       6.0  
Total Non-GAAP operating expenses   $ 21.5     $ 23.5